M&A Deal Summary

GSK Acquires BELLUS Health

On April 18, 2023, GSK acquired life science company BELLUS Health for 2.0B USD

Acquisition Highlights
  • This is GSK’s 24th transaction in the Life Science sector.
  • This is GSK’s 8th largest (disclosed) transaction.
  • This is GSK’s 1st transaction in Canada.
  • This is GSK’s 1st transaction in Quebec.

M&A Deal Summary
Date 2023-04-18
Target BELLUS Health
Sector Life Science
Buyer(s) GSK
Deal Type Add-on Acquisition
Deal Value 2.0B USD

Target

BELLUS Health

Laval, Quebec, Canada
BELLUS Health is developing drugs for rare diseases with a particular focus on renal disorders. The company also has an agreement with AmorChem Holdings Inc. to develop drug candidates for the treatment of AL amyloidosis. BELLUS Health was founded in 1993 and is based in Laval, Canada.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

GSK

Brentford, United Kingdom
Category Company
Founded 1715
Sector Life Science
Employees70,212
Revenue 30.3B GBP (2023)
DESCRIPTION
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.

GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.

DEAL STATS #
Overall 30 of 32
Sector (Life Science) 24 of 26
Type (Add-on Acquisition) 22 of 24
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2023) 1 of 1
Size (of disclosed) 8 of 28
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-31 Affinivax

Cambridge, Massachusetts, United States

Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines, using its patented biotin-rhizavidin binding approach to optimize the body’s protective immune response to address infectious and other immune-mediated diseases. Affinivax is based in Cambridge, Massachusetts.

Buy $2.1B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-01-09 Aiolos Bio

San Francisco, California, United States

Aiolos Bio is a clinical-stage, private, biopharmaceutical company dedicated to revolutionising the treatment landscape for respiratory disease. Aiolos Bio is based in San Francisco, California.

Buy $1.4B
Mergr

Product

Company

Legal